· Meda expects to launch Edluar in the USA during 2nd half of 2009 · Orexo receives a milestone payment of USD 5 million from Meda · Orexo's second major product approval in 12 months UPPSALA, Sweden, ...
The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. The maker of ...
MISSISSAUGA, Ontario, July 25, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that its wholly owned subsidiary, Valeant Canada Limited, has ...
STOCKHOLM, Sweden -- Meda has acquired the exclusive world-wide commercialization rights from Orexo (STO:ORXA) of two patented drugs in late development phase; Sublinox and OX-NLA. Sublinox (treatment ...
Meda has acquired the rights to two late-stage drugs from fellow Swedish firm Orexo, a sleep disorder treatment and an allergy compound. Meda has acquired the rights to two late-stage drugs from ...
Transaction covering insomnia treatment and rhinitis nasal spray calls for $20 million upfront. Meda acquired the worldwide commercialization rights for two patented drugs in late-phase development ...
OTTAWA – The company that markets the sleep-aid medication Sublinox says the drug can cause abnormal sleep behaviours, in which a person gets out of bed while not fully awake and performs activities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results